The Dengue Vaccine Market is expected to experience steady growth in the forecast period.
Dengue is a mosquito-borne viral infection caused by the Flaviviridae family, primarily transmitted by infected Aedes mosquitoes. It is prevalent in tropical and subtropical regions and can cause a range of symptoms, from mild fever to severe conditions like Dengue hemorrhagic fever (DHF) and Dengue shock syndrome (DSS). Common symptoms include high fever, severe headaches, eye pain, joint and muscle pain, rash, and mild bleeding. In severe cases, Dengue can lead to organ damage, bleeding, and a drop in blood platelet count, which can be fatal if not managed properly. A "Dengue vaccine" is a vaccine designed to provide immunity or reduce the severity of Dengue fever. The development of a Dengue vaccine has been a significant area of research and public health interest due to its global impact.
Market Drivers
The global incidence of dengue has significantly increased over the past two decades, posing a significant public health challenge. From 2000 to 2019, the World Health Organization reported a ten-fold surge in reported cases, from 500,000 to 5.2 million. In 2019, an unprecedented peak was reported across 129 countries. After a slight decline between 2020-2022 due to the COVID-19 pandemic and lower reporting rates, an upsurge in dengue cases in 2023 was observed globally, characterized by a significant increase in the number, scale, and simultaneous occurrence of multiple outbreaks, spreading into previously unaffected regions. Dengue transmission is cyclic, with large outbreaks every 3-4 years. Since 2023, ongoing transmission and an unexpected spike in cases have resulted in nearly a historic high of over five million cases and over 5000 dengue-related deaths in over 80 countries/territories and five WHO regions.
The dengue vaccine market is anticipated to expand as a result of advancements in adjuvants, manufacturing techniques, vaccine technology, and other areas. Persistent innovation could result in the development of safer and more effective vaccinations. For instance, In December 2022, The Butantan Institute's dengue vaccine, Butantan-DV, showed 79.6% efficacy in preventing the disease, according to a phase 3 clinical study. The study, conducted between February 2016 and July 2021, involved 16,235 volunteers aged 2 to 59 years. The incidence of laboratory-confirmed symptomatic dengue cases was observed after 28 days of vaccination until the second year of follow-up. The study will continue until all participants complete five years of follow-up in 2024. Also, In September 2020, Panacea Biotec completed the Phase I/II study of its Tetravalent recombinant chimeric Dengue candidate vaccine, DengiAll. The vaccine induced robust neutralizing antibody responses against all four Dengue virus serotypes and was found to be safe and well-tolerated with no serious adverse effects. Over 80% of participants showed a tri-valent response.
The sharing of information, resources, and expertise is facilitated by cooperative efforts between researchers, pharmaceutical companies, governmental bodies, and international organizations. International cooperation allows access to a variety of datasets and quickens the development of a dengue vaccine. For Instance, In December 2022, Instituto Butantan and Merck announced a collaboration agreement to develop investigational dengue vaccines. Both institutions are evaluating formulations similar to the NIH TV003 formulation. Under the agreement, they shared clinical data and learnings from their respective dengue vaccine development programs. This collaboration demonstrated Merck's engagement with the global public health community in developing vaccines for tropical and subtropical diseases.
Asia Pacific is expected to grow significantly.
The Asia Pacific region could be expected to significantly contribute to the dengue vaccine market growth due to several factors. The high burden of Dengue fever in many countries, along with its associated economic and healthcare costs, makes vaccine development a priority for public health. The densely populated and rapidly urbanized region creates favorable conditions for the proliferation of Aedes mosquitoes, the primary vectors of the Dengue virus. Government initiatives, collaborations between international pharmaceutical companies, research institutions, and local organizations, and increasing awareness about the disease's impact on public health can drive demand for Dengue vaccines. These factors, combined with increasing public awareness, could drive the development and introduction of new Dengue vaccines. For instance, In December 2022, Takeda, a Japanese pharmaceutical company, started submitting regulatory submissions for a dengue vaccine candidate, TAK-003, in the EU and dengue-endemic countries. This move is attracting competition from other companies, who are focusing on developing vaccines for individuals aged four to 60, particularly in the Asia Pacific region.
Market Restraints
Hesitancy towards vaccinations can be influenced by worries about vaccine safety, especially in light of the disputes around some Dengue vaccines. Successful immunization efforts depend on raising public knowledge and confidence.
Market Developments
Company Products
Segmentation